	Metabolic vulnerabilities in advanced prostate cancer: the interplay of ferroptosis, cuproptosis, and the inflammatory microenvironment. Med Oncol Motafeghi F, Mortazavi P, Hossein Hosseinzadeh M, Ghassemi Barghi N. PMID: 42283905 [PubMed - in process]
	Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions. Clin Adv Hematol Oncol Linville LM, Canzoniero JV, Marshall CH, Armstrong DK, Markowski MC, Carducci MA. PMID: 42283711 [PubMed - in process]
	Multicenter Study Suggests Unsupervised Learning Derived From MRI Identifies Prognostic Subgroups in Prostate Cancer Patients After Prostatectomy. Radiol Res Pract Hu G, Liu X, Chen Z, Zhou B, Gan H, Chen R, Zhou L, Gu Y, Liu X. PMID: 42283020 [PubMed]
	Extracellular vesicles in prostate cancer: current understanding and future perspectives. J Natl Cancer Cent Perumalsamy B, Seshacharyulu P, Vengoji R, Shonka N, Teply BA, Batra SK, Muniyan S. PMID: 42282127 [PubMed]
	Construction and external validation of radiomics models to detect primary prostate cancer with machine learning: a multicenter study based on (68)Ga-PSMA PET/CT. J Natl Cancer Cent Chen J, Jiang X, Yang G, Tang Y, Qi L, Chen M, Hu S, Gao X, Gan Y, Zhang M, Chen S, Cai Y. PMID: 42282124 [PubMed]
	Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study. Res Rep Urol Furubayashi N, Tsujita J, Takayama A, Shiraishi Y, Nakamura M, Negishi T. PMID: 42281847 [PubMed]
	Natural Flavonoids Genistein and Baicalein as Well-Tolerated Radiosensitizers to Enhance the Efficacy of (177)Lu-PSMA617 in Prostate Cancer: InÂ Vitro and InÂ Vivo Studies. Research (Wash D C) He C, Shao Y, Bao Y, Li J, Si H, He J. PMID: 42281770 [PubMed]
	Feasibility and Safety of a Ketogenic Diet During Systemic Therapy for Metastatic Renal Cell Carcinoma: Results from the Cetorein Pilot Study. Nutrients Rolley C, Zidane M, Nedelcu C, Barth M, Saulnier P, Procaccio V, Bigot P. PMID: 42280354 [PubMed - in process]
	Automated H-Scoring in Muscle-Invasive Bladder Cancer IHC: An Internal Validation Study. Diagnostics (Basel) Yap M, Mihai IM, Alanazi MAA, Olteanu GE, Contreras-Sanz A, Black P, Wang G. PMID: 42279541 [PubMed]
	Pre-Analytical and Analytical Challenges in Whole-Exome Sequencing of Formalin-Fixed Paraffin-Embedded Breast and Prostate Cancer Tissue: A Real-World Multicenter Study. Diagnostics (Basel) Rosa ML, Bordignon C, Schuch JB, Baumont AC, Bessel M, Curzel GD, Cadore NA, Varela APM, Dos Santos GT, Andreis TF, Oliveira FH, Vasconcellos VF, Barros LAR, Souza CP, Barra WF, Louzeiro DLC, Notari A, de Menezes JJ, Liedke PER, Bertollo GA, Gongora ABL, Ascenco HG, Kowalski-Neto E, Oppermann CP, Werutsky G, Santos EM, Brandão FS, Freitas R Jr, Nogueira-Rodrigues A, Mancini ALC, Rosa DD, Macedo GS. PMID: 42279462 [PubMed]
	The Prognostic Value of Clinical and Pathological Response to Neoadjuvant Therapy in Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Systematic Review and Clinical Implications. Cancers (Basel) Chernysheva D, Hernandez-Peñalver P, Maroto P, Palou J, Breda A, Rodriguez-Faba O. PMID: 42279411 [PubMed]
	Venous Tumor Thrombus Level in Renal Cell Carcinoma: Impact on Surgical and Oncologic Outcomes. Cancers (Basel) Korbecka Z, Jab, Król R. PMID: 42279382 [PubMed]
	Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer. Cancers (Basel) Guida C, Evangelista L, Spadafora M, Facchini G, Mansi L. PMID: 42279380 [PubMed]
	Clinical Value of a Novel Apparent Diffusion Coefficient-Based Bi-Color Map for Detecting Clinically Significant Prostate Cancer: A Retrospective Study. Cancers (Basel) Okada M, Araki Y, Hirasawa Y, Nagao G, Kashima T, Hayashi K, Satake N, Saito K, Ohno Y. PMID: 42279378 [PubMed]
	Microenvironment at a Distance: Multi-Endocrine-Organ Radiomics to Identify Systemic Signatures in PSMA-Negative Prostate Cancer. Cancers (Basel) Abdollahi H, Harsini S, Yousefirizi F, Hatami B, Bénard F, Shariftabrizi A, Alberts I, Rahmim A. PMID: 42279350 [PubMed]
	Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches. Cancers (Basel) Khazaei Z, Pouliot F, Archambault L. PMID: 42279335 [PubMed]
	Study of Bladder Cancer Detection in Standard White Light Versus AI-Supported Endoscopy-02 (RAISE-02)-A Randomized Controlled Non-Inferiority Trial. Cancers (Basel) Hjort PB, Skovhus K, Jensen JB, Ernst A. PMID: 42279322 [PubMed]
	Evaluating Worldwide Disparities in Bladder Cancer Clinical Trial Availability. Cancers (Basel) Shah KU, Castro DV, Li X, Zugman M, Jaime-Casas S, Abreu de Goes V, Zang PD, Reid S, Paul T, Goud J, Dickter S, Dickter L, Lau L, Agarwal R, Lee A, Chaudhary N, Ebrahimi H, Mercier B, Dizman N, Bergerot CD, Chehrazi-Raffle A, Nguyen CB, Tripathi A, Barragan-Carrillo R, Pal SK. PMID: 42279313 [PubMed]
	Bone Marrow-Derived Mesenchymal Stem Cells Differentiate into Cancer-Associated Fibroblasts and Promote Tumor Growth in Renal Cell Carcinoma. Cancers (Basel) Kitano H, Yuge R, Shikuma H, Yukihiro K, Hatayama T, Nakano Y, Tasaka S, Okazaki M, Nomura N, Tasaka R, Iwane K, Kohada Y, Miyamoto S, Naito M, Takigawa H, Kobatake K, Sekino Y, Oka S, Hinata N. PMID: 42279300 [PubMed]
	Circulating Tumor DNA as Emerging Predictive and Prognostic Biomarker in Prostate Cancer. Cancers (Basel) Thapa B, Venturini J, Choudhury AD, Francini E. PMID: 42279286 [PubMed]

Articles 1 - 20 / 178917

Page 1 of 8946



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy